Bayer drug delays MS in half of patients: MRI study

CHICAGO (Reuters) - A long-term study of brain scans in multiple sclerosis patients showed only about half of the patients who took the drug interferon beta 1-b got a long-lasting benefit, U.S. researchers said on Monday.

Patients in the small, three-year study were treated with the Bayer drug, which is sold under the trade name Betaseron in the United States or Betaferon elsewhere.

The drug is designed to reduce the number of disease flareups.

Multiple sclerosis occurs when the immune system attacks the myelin sheath protecting nerve cells. It affects 2.5 million people globally and can cause symptoms ranging from vague tingling to blindness and paralysis.

The researchers were looking to see how the drug affected active brain lesions that can be viewed on magnetic resonance imaging or MRI. These lesions often show up before patients develop symptoms of the disease.

“Many clinical studies have demonstrated the ability of interferon beta to reduce contrast-enhancing lesions,” Francesca Bagnato of the National Institute of Neurological Disorders and Stroke and colleagues wrote in the Archives of Neurology.

In the study, 15 people with MS had monthly exams and MRIs for six months before treatment and three years during treatment.

“The results show that on close monthly MRI inspection, approximately half of the patients fail therapy from an MRI perspective,” Francesca Bagnato and colleagues wrote.

They did find that a few patients had a delayed response to the drug. Researchers noted that the study was small and the findings were not definitive.

A recent 5-year study suggested that early treatment with Betaseron was more effective when given at the first sign of the disease than if treatment is delayed.

MS drugs are often given only after the second attack because the disease is difficult to diagnose.


Related Posts:

By Michael Kahn LONDON (Reuters) - A drug developed to fight leukemia appears to stop multiple sclerosis in its early stages and restore lost function to patients, British researchers said on Wednesday. The three-year study of Bayer AG and Genzyme Corp’s alemtuzumab for the first time show long-term improvement in disability, Alasdair Cole, a neurologist at the

Full Post: Leukemia drug appears to stop early stage MS

WASHINGTON (Reuters) - The popular multiple sclerosis drug Tysabri appears to promote a rare brain infection by suppressing immune system cells in the brain, researchers said on Tuesday. The researchers, who conducted an autopsy on an MS patient who died while taking the drug, said it may be possible to make the drug safer by giving

Full Post: MS drug Tysabri may promote brain infection: study

By Will Dunham WASHINGTON (Reuters) - Brain scans of people with an abnormality that is a hallmark of Alzheimer’s disease are strengthening the notion that greater education levels somehow protect against this common form of dementia. People with more education did better on memory and problem solving tests than others with similar amounts of brain plaques related

Full Post: Education blunts effects of Alzheimer’s: study

NEW YORK (Reuters) - Biogen Idec Inc said on Monday it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year. The latest case of the brain infection, known as progressive multifocal leukoencephalopathy (PML), was

Full Post: Biogen says new brain infection linked to Tysabri

By Will Dunham WASHINGTON (Reuters) - Deep brain stimulation dramatically improves Parkinson’s disease symptoms such as trembling and slowness of movement, offering hope to many with the incurable ailment, researchers said on Tuesday. Six months of deep brain stimulation with a device made by Minneapolis-based Medtronic Inc led to better quality of life and 4-1/2 additional hours

Full Post: Study backs deep brain stimulation for Parkinson’s

Site Navigation

Most Read